In a newly published commentary piece, Narasimha Kumar, the Global Head of Technology and Data Services at BC Platforms, argues that the pharmaceutical industry’s rush toward advanced artificial intelligence is severely bottlenecked by poor data architecture. While life science executives are eager to deploy AI to radically accelerate clinical evidence generation, Kumar emphasizes that modern models are only as good as the infrastructure beneath them.
According to Kumar, pharma data remains stubbornly fragmented, locked in isolated organizational silos that lack proper harmonization and clinical interoperability. For AI to successfully generate accurate real-world evidence, companies must shift focus from flashy algorithms to foundational data engineering. This means transforming unorganized, messy legacy datasets into high-fidelity, standardized information pipelines.
Kumar stresses that a patient-centric approach to data harmonization is no longer optional. Without a unified, clean, and globally cross-referenced digital backbone, advanced deep learning models cannot extract meaningful insights. For tech and clinical operations leaders, Kumar’s commentary serves as an urgent reminder: true AI readiness does not come from investing in software tools, but from getting the structural data foundation right first.